BME100 f2015:Group13 8amL1: Difference between revisions
(4 intermediate revisions by the same user not shown) | |||
Line 19: | Line 19: | ||
| [[Image:BME103student.jpg|100px|thumb|Name: Parker Storry]] | | [[Image:BME103student.jpg|100px|thumb|Name: Parker Storry]] | ||
| [[Image:BME103student.jpg|100px|thumb|Name: Luis Morales]] | | [[Image:BME103student.jpg|100px|thumb|Name: Luis Morales]] | ||
| [[Image: | | [[Image:IMG 3086.jpg|100px|thumb|Name: Derek Scott]] | ||
|} | |} | ||
Line 25: | Line 25: | ||
==Independent and Dependent Variables== | ==Independent and Dependent Variables== | ||
<u>Independent Variable:</u> | <u>Independent Variable:</u> The goal of our study is to measure the minimum amount of lipopolysaccharide needed to induce the presence of inflammatin, thus, the amount, in milligrams(mg), of lipopolysaccharide given to the test subject is our independent variable.<br><br> | ||
<u>Dependent Variable:</u> Presence and amount of inflammotin in test subject after being given the assigned dosage of lipopolysaccharide. | <u>Dependent Variable:</u> Presence and amount of inflammotin in test subject after being given the assigned dosage of lipopolysaccharide is the result we are examining through differing dosages of lipopolysaccharide, thus it is our dependent variable. | ||
==Experimental Design== | ==Experimental Design== | ||
Line 67: | Line 67: | ||
<u>Requirements:</u> | <u>Requirements:</u> | ||
*Within the ages of 60-80 years old. <br> | *Within the ages of 60-80 years old. <br> | ||
*Only subjects without the protein Inflammotin in their system naturally will be selected for the test phase to prevent prior levels | *Only subjects without the protein Inflammotin in their system naturally will be selected for the test phase to prevent prior levels skewing results.<br> | ||
*Subjects will have to provide health records for review and only subjects with minimal health problems will be accepted.<br> | *Subjects will have to provide health records for review, and only subjects with minimal health problems will be accepted.<br> | ||
*Current medications and health issues will be evaluated as to assure that being given lipopolysaccharide will | *Current medications and health issues will be evaluated as to assure that being given lipopolysaccharide will neither negatively affect the health of the test subjects, nor the tests.<br><br> | ||
<b><u>Important</u></b> To | <b><u>Important</u></b> To ensure adequate randomization and reduce bias in the results from oversampling a singular group in society (i.e. a particular gender, race, or age), during the selection process people from various ethnic backgrounds and genders will be selected. To diminish the bias of oversampling an age range, each group will be given one subject from each age range. | ||
Line 82: | Line 82: | ||
<b>1.</b> If test subjects know they are receiving a dosage of lipopolysaccharide, as opposed to a placebo, they may naturally develop an increase in inflammatin and bias the results.<br> | <b>1.</b> If test subjects know they are receiving a dosage of lipopolysaccharide, as opposed to a placebo, they may naturally develop an increase in inflammatin and bias the results.<br> | ||
<b>2.</b> Improper collecting and testing procedures of blood samples could lead to skewed results. <br> | <b>2.</b> Improper collecting and testing procedures of blood samples could lead to skewed results. <br> | ||
<b>3.</b> Unaccounted outside influences, such as diet, stress, and etc., could result in an increase of inflammatin in the test subject that would result in a potential false positive. | <b>3.</b> Unaccounted outside influences, such as diet, stress, and etc., could result in an increase of inflammatin in the test subject that would result in a potential false positive. <br> | ||
<b>4.</b> Variable times of administration could impact efficacy of the dosage, or skew data. | |||
<br><br> | <br><br> | ||
'''Controls for the sources of error:''' <br> | '''Controls for the sources of error:''' <br> | ||
<b>1.</b> The experiment will be designed as a double-blind experiment. Thus, researchers and subjects will not know, and cannot instinctively react to the knowledge of being administered lipopolysaccharide.<br> | |||
To combat the improper collecting of data, multiple samples will be | <b>2.</b> To combat the improper collecting of data, multiple samples will be collected and compared to previous samples of the test subject to eliminate any outliers in the information collected. <br> | ||
To | <b>3.</b> To diminish the presence and influence of unaccounted outside influences, interviews and surveys will be conducted to allow the researchers knowledge of potential issues and give adequate rational for understanding any inflammotin levels that lay outside the expected results. <br> | ||
<b>4.</b> All administrations of lipopolysaccharide will be given at the same time, 8:00 AM on the assigned dates. | |||
Latest revision as of 21:52, 9 September 2015
BME 100 Fall 2015 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | ||||||
OUR TEAMLAB 1 WRITE-UPIndependent and Dependent VariablesIndependent Variable: The goal of our study is to measure the minimum amount of lipopolysaccharide needed to induce the presence of inflammatin, thus, the amount, in milligrams(mg), of lipopolysaccharide given to the test subject is our independent variable. Experimental DesignGroups
Note: Prior work has shown that a 10mg dose of lipopolysaccharide will induce the presence of Inflammotin.
Subject SelectionRequirements:
Sources of Error and BiasSources of error: Controls for the sources of error:
|